What It Does
This discovery provides crucial clues for the development of novel hepatoprotective drugs or therapeutic strategies, underscoring the promising prospects of GA in the realm of liver health
[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
Alpina Oil, Sodium Chloride, Choline Chloride, L-Tyrosine, L-Ascorbic Acid, Inositol, Taurine, Sodium L-Ascorbate, Ferrous Sulfate, Zinc Sulfate, L-Carnitine, Sodium Citrate, DL-Alpha Tocopheryl Acetate, Calcium D-Pantothenate, Niacinamide, Copper Sulfate, DL-Alpha Tocopherol, Vitamin A Palmitate, Riboflavin, Thiamine Hydrochloride, Pyridoxine Hydrochloride, Potassium Iodide, Folic Acid, Manganese Sulfate, Sodium Selenite, Phylloquinone, D-Biotin, Vitamin D 3 , Cyanocobalamin, Ascorbyl Palmitate, Calcium Hydroxide, Potassium Hydroxide, Nucleotides (Disodium Uridine 5 -Monophosphate, Cytidine 5 -Monophosphate, Disodium Inosine 5 -Monophosphate, Adenosine 5 -Monophosphate, Disodium Guanosine 5 - Monophosphate)
